TG Therapeutics Inc

6 nov 2026, 22:51 UTC

TG Therapeutics, Inc. is trading modestly higher in after-market hours, reflecting broader market gains following strong U.S. labor market data for October.

5 nov 2026, 23:03 UTC

TG Therapeutics, Inc. shares advanced modestly during after-market hours on Thursday, fluctuating from negative territory to a high nearing 1%.

4 nov 2026, 23:26 UTC

TG Therapeutics, Inc. is roughly flat in after-market trading, slightly declining from an early high but remaining above its 20-day moving average.

3 nov 2026, 22:51 UTC

TG Therapeutics, Inc. is advancing in after-market trading, moving higher alongside the broader market following a recovery from an initial dip after Tuesday's close.

2 nov 2026, 23:51 UTC

TG Therapeutics, Inc. shares advanced in after-market trading, moving higher alongside the broader market, despite some volatility during the session.

31 ott 2026, 00:02 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, reaching its highest cumulative return of the day and significantly surpassing Friday's close.

30 ott 2026, 23:31 UTC

TG Therapeutics, Inc. shares traded modestly higher during after-market hours on Friday, continuing a trend of higher daily closes since the prior close.

29 ott 2026, 22:26 UTC

TG Therapeutics, Inc. is experiencing a notable decline in after-market trading, retracing from earlier gains and marking a significant drop since Thursday's close.

28 ott 2026, 23:06 UTC

TG Therapeutics, Inc. shares are trading lower in after-market hours ahead of earnings on Monday, fluctuating between a loss of over two percent and a slight gain.

27 ott 2026, 20:51 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, recovering from earlier losses to reach a notable peak above its 20-day moving average.

26 ott 2026, 20:13 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, following three consecutive sessions of gains and an unusual lack of variation.

23 ott 2026, 20:03 UTC

TG Therapeutics announced initial Phase 1 study results showing 89% of participants with progressive multiple sclerosis had stable or improved disability scores at Day 90.

22 ott 2026, 20:07 UTC

TG Therapeutics Inc shares fell slightly, retracing from an early peak and ending near the lower end of their one-month range.

21 ott 2026, 19:36 UTC

TG Therapeutics presented new clinical data for BRIUMVI at the MSToronto2026 conference, showing 88% of patients free from disability progression after continuous treatment.

20 ott 2026, 22:36 UTC

TG Therapeutics Inc is trading lower in after-market hours, having retraced from an earlier high and positioned near the lower end of its one-month trading range.

19 ott 2026, 20:07 UTC

Shares of TG Therapeutics Inc are declining, finishing well below the 20-day moving average and near the lower end of the one-month range.

16 ott 2026, 19:53 UTC

TG Therapeutics Inc shares are declining sharply, trading well below their 20-day moving average and near the lower end of their one-month range.

15 ott 2026, 20:07 UTC

TG Therapeutics Inc shares advanced, peaking in the late morning and settling near the day's high, remaining above its 20-day moving average.

14 ott 2026, 23:21 UTC

TG Therapeutics Inc shares declined in after-market trading, moving lower alongside the broader market amid significant declines in technology stocks and rising crude oil prices.

12 ott 2026, 19:56 UTC

TG Therapeutics published a five-year study showing BRIUMVI has a lower risk of disability progression compared to ocrelizumab and ofatumumab in relapsing multiple sclerosis.

10 ott 2026, 00:01 UTC

TG Therapeutics Inc shares are trading modestly higher in after-market hours, continuing a trend of four consecutive sessions finishing higher.

9 ott 2026, 23:20 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, having fluctuated between a decline and a slight gain since Friday's close.

8 ott 2026, 19:15 UTC

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7 ott 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6 ott 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

5 ott 2026, 20:06 UTC

TG Therapeutics Inc. shares fell sharply, pulling back from Friday's close after earlier reaching a session high, amid multiple year-end catalysts.

2 ott 2026, 19:26 UTC

TG Therapeutics is trading higher amid social media buzz over a buy recommendation and an $86 price target for its anti-CD20 treatment, Briumvi.

1 ott 2026, 23:05 UTC

TG Therapeutics Inc is trading modestly higher in after-market hours, despite remaining below its 20-day moving average after three consecutive sessions finishing lower.

30 set 2026, 20:07 UTC

TG Therapeutics Inc shares fell modestly following Tuesday's close, amid a broader market decline, and are currently near the midpoint of their one-month trading range.

28 set 2026, 20:07 UTC

TG Therapeutics Inc shares are declining, continuing a downward trend since Friday's close amid a broader market downturn, despite a brief recovery attempt.